NYSE: AGLAgilon Health Inc Stock
$29.58+1.63 (+5.83%)
Updated May 1, 2026
AGL Price
$29.58
Fair Value Price
N/A
Market Cap
$490.87M
52 Week Low
$7.48
52 Week High
$119.50
P/E
-1.25x
P/B
3.87x
P/S
0.05x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.93B
Earnings
-$391.35M
Gross Margin
-2.7%
Operating Margin
-6.46%
Profit Margin
-6.6%
Debt to Equity
9.03
Operating Cash Flow
-$106M
Beta
1.02
Next Earnings
May 12, 2026
Ex-Dividend
N/A
Next Dividend
N/A
AGL Overview
Agilon Health Inc. provides healthcare services to 238,000 seniors in the U.S through a network of primary care physicians.The company was known as Agilon Health Topco, Inc. until it changed its name in 2021/03. Agilon Health was founded in 2016 and is based in Austin, TX.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AGL's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Care Facility
Industry Rating
A
AGL
Ranked#38 of 39
Ranked#38 of 39
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $6.61 | A | |
| $8.32 | A | |
| $22.75 | A |
Be the first to know about important AGL news, forecast changes, insider trades & much more!
AGL News
Overview
Due Diligence Score
–
Industry Average (30)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AGL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AGL is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AGL is good value based on its book value relative to its share price (3.87x), compared to the US Medical Care Facilities industry average (5.04x)
P/B vs Industry Valuation
AGL is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more AGL due diligence checks available for Premium users.
Valuation
AGL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.25x
Industry
18.12x
Market
18.83x
AGL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.87x
Industry
5.04x
AGL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AGL's financial health
Profit margin
Revenue
$1.6B
Net Income
-$188.9M
Profit Margin
-12%
AGL's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
AGL's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.3B
Liabilities
$1.1B
Debt to equity
9.03
AGL's short-term assets ($1.10B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AGL's short-term assets ($1.10B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AGL's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AGL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$20.5M
Investing
$22.6M
Financing
-$17.0k
AGL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AGL vs Medical Care Facility Stocks
Agilon Health Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.